As of Fall 2013, Verenium Corporation (NASDAQ:VRNM) became part of BASF. Originally formed through the merger in 2011 of Diversa (NASDAQ:DVSA) and biofuels specialist Celuno, Verennium functions(ed) as an industrial biotechnology company developing high-performance enzymes tailored to be environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets. The firm's enzymes are developed by tapping into the vast genetic reservoir of bacteria and fungi â natureâs most abundant resource â to create high-performance industrial enzyme solutions making progress towards creating an eco-sensitive, enzymatic bioprocesses that replace inefficient, often harsh chemical processes. Maintaining the San Diego facilities after to earlier merger, the firm had been headquartered in Cambridge, MA. Having a growing portfolio of specialty enzyme products and "unique technical and operational capabilities, Verenium Corporation had been in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and animal health markets. The Company possessed integrated, end-to-end capabilities and cutting-edge technology in pre-treatment, novel enzyme development, fermentation and project development for next-generation biofuels. Through a joint venture with BP, the Company had moved rapidly to commercialize its proprietary technology for the production of ethanol from a wide array of non-food feedstocks, including dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for biofuels, a multitude of large-scale industrial opportunities existed for the Company for products derived from the production of low-cost, biomass-derived sugars. Diversa had been utilizing its fully integrated approach to develop novel enzymes and other biologically active compounds, such as orally active drugs, produced by these genes and gene path
